CD8A and neoplasm: In subsequent work, a specialized subset of tumor-associated HLA-DR+ neutrophils was identified in early-stage tumors, which is capable of cross-presenting exogenous tumor antigens to CD8+ T cells to stimulate tumor-specific effector T cell responses (Singhal et al., 2016).